SAN DIEGO–(BUSINESS WIRE)– Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten offering of 4,153,717 shares…Read More
Janux Therapeutics Announces Pricing of 60 Million Underwritten Offering of Common Stock and PreFunded Warrants
